Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
Sign Up to like & getrecommendations! Published in 2020 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/s41392-020-00251-2
Abstract: Epidermal growth factor receptor (EGFR) activation plays a pivotal role in EGFR-driven non-small cell lung cancer (NSCLC) and is considered as a key target of molecular targeted therapy. EGFR tyrosine kinase inhibitors (TKIs) have been… read more here.
Keywords: dpba; egfr; novel egfr; egfr ligand ... See more keywords